


ACCP Virtual Journal Club Webinars!

Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics

2021 ACCP Virtual Journal Club Webinar

Live Session: Wednesday, December 8, 2021, from 2:00 to 3:00 PM ET

On Demand: December 8, 2021, to December 8, 2024



Why is this webinar important to you?

Cobimetinib is a kinase inhibitor indicated for use in combination with vemurafenib for treatment of unresectable/metastatic melanoma with specific BRAF mutations. Cobimetinib is extensively metabolized in liver; thus, patients with hepatic impairment (HI) might have increased cobimetinib exposure. By attending this educational activity, you will learn about the impact of HI on the pharmacokinetics (PK) and safety of cobimetinib.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants.

Learning Objectives

After completing this activity, the learner will be able to:

1. Appreciate the application of Clinical Pharmacology expertise to assess if dose adjustment is needed for a drug in subjects with hepatic dysfunction.
2. Understand what factors need to be considered for a hepatic impairment study.
3. Learn about the complex interplay between the disease state and drug characteristics.

Schedule & Fees

ACCP webinar programs occur several times per year. Registration for the webinars are required, but are free of charge to all learners.

Helpful Tips

For best audio and visual quality, we recommend viewing the webinar in the Chrome browser. If you do not have Chrome, you may download it [here](#).

Test your browser compatibility before the webinar by clicking [here](#).

Download the article and slide handouts and access the webinar [here](#).

For help during the webinar, please call (571) 291-3493 ext 4.